The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
In this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized controlled trials. Odds ratios (ORs) were calculat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2023/6638089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306451526287360 |
|---|---|
| author | Fei Lin Qiu’e Yao Bin Yu Zehui Deng Jingyue Qiu Rong He |
| author_facet | Fei Lin Qiu’e Yao Bin Yu Zehui Deng Jingyue Qiu Rong He |
| author_sort | Fei Lin |
| collection | DOAJ |
| description | In this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized controlled trials. Odds ratios (ORs) were calculated using fixed- or random-effect models. A total of three studies involving 341 patients were identified. Overall, the analysis revealed that teprotumumab demonstrated superior integrated proptosis response compared to placebo in both the intention-to-treat (ITT) population (OR = 17.81, 95% CI = [10.32, 30.76], I2 = 50%) and per-protocol population (OR = 24.53, 95% CI = [12.96, 46.45], I2 = 14%). Furthermore, patients receiving teprotumumab showed significant improvement in overall response (OR = 8.35, 95% CI = [4.74, 14.71], I2 = 79%), diplopia response (OR = 5.53, 95% CI = [3.24, 9.44], I2 = 0%), and achieving a clinical activity score (CAS) of 0 or 1 (OR = 6.26, 95% CI = [3.87, 10.12], I2 = 0%). Moreover, patients treated with teprotumumab experienced greater improvements in proptosis (MD = −2.49, 95% CI = [−2.54, −2.45], I2 = 98%) and Graves’ ophthalmopathy-specific quality of life (GO-QOL, MD = 11.48, 95% CI = [11.03, 11.93], I2 = 95%). However, it is important to note that patients receiving teprotumumab had a higher risk of adverse events, including serious adverse events, gastrointestinal adverse reactions, and muscle spasms. In summary, teprotumumab demonstrated greater improvement in proptosis response, proptosis, diplopia response, overall response, GO-QOL, and CAS. Nonetheless, it should be considered that its use is associated with a higher risk of adverse events. |
| format | Article |
| id | doaj-art-2dec438f816441af97409ffd29bb3527 |
| institution | Kabale University |
| issn | 1742-1241 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Clinical Practice |
| spelling | doaj-art-2dec438f816441af97409ffd29bb35272025-08-20T03:55:06ZengWileyInternational Journal of Clinical Practice1742-12412023-01-01202310.1155/2023/6638089The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled TrialsFei Lin0Qiu’e Yao1Bin Yu2Zehui Deng3Jingyue Qiu4Rong He5Department of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of Respiratory and Critical Care MedicineIn this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized controlled trials. Odds ratios (ORs) were calculated using fixed- or random-effect models. A total of three studies involving 341 patients were identified. Overall, the analysis revealed that teprotumumab demonstrated superior integrated proptosis response compared to placebo in both the intention-to-treat (ITT) population (OR = 17.81, 95% CI = [10.32, 30.76], I2 = 50%) and per-protocol population (OR = 24.53, 95% CI = [12.96, 46.45], I2 = 14%). Furthermore, patients receiving teprotumumab showed significant improvement in overall response (OR = 8.35, 95% CI = [4.74, 14.71], I2 = 79%), diplopia response (OR = 5.53, 95% CI = [3.24, 9.44], I2 = 0%), and achieving a clinical activity score (CAS) of 0 or 1 (OR = 6.26, 95% CI = [3.87, 10.12], I2 = 0%). Moreover, patients treated with teprotumumab experienced greater improvements in proptosis (MD = −2.49, 95% CI = [−2.54, −2.45], I2 = 98%) and Graves’ ophthalmopathy-specific quality of life (GO-QOL, MD = 11.48, 95% CI = [11.03, 11.93], I2 = 95%). However, it is important to note that patients receiving teprotumumab had a higher risk of adverse events, including serious adverse events, gastrointestinal adverse reactions, and muscle spasms. In summary, teprotumumab demonstrated greater improvement in proptosis response, proptosis, diplopia response, overall response, GO-QOL, and CAS. Nonetheless, it should be considered that its use is associated with a higher risk of adverse events.http://dx.doi.org/10.1155/2023/6638089 |
| spellingShingle | Fei Lin Qiu’e Yao Bin Yu Zehui Deng Jingyue Qiu Rong He The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials International Journal of Clinical Practice |
| title | The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials |
| title_full | The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials |
| title_fullStr | The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials |
| title_full_unstemmed | The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials |
| title_short | The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials |
| title_sort | efficacy and safety of teprotumumab in thyroid eye disease evidence from randomized controlled trials |
| url | http://dx.doi.org/10.1155/2023/6638089 |
| work_keys_str_mv | AT feilin theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT qiueyao theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT binyu theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT zehuideng theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT jingyueqiu theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT ronghe theefficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT feilin efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT qiueyao efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT binyu efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT zehuideng efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT jingyueqiu efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials AT ronghe efficacyandsafetyofteprotumumabinthyroideyediseaseevidencefromrandomizedcontrolledtrials |